



ESPERITE (ESP) negotiates 18-month extension for EUR 4,750,000 in unsecured convertible loan notes

Amsterdam, The Netherlands – 14 June 2019

Esperite N.V. (Euronext: ESP, “**Esperite**”) is pleased to announce that it has agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible loan notes (the **Loan Notes**). Esperite’s CEO, Mr. Frederic Amar, (in)directly holds EUR 3,350,000 of the Loan Notes, the remaining EUR 1,400,000 in Loan Notes are held by third party investors. Under the original terms of most of the Loan Notes, the maturity date was 31 December 2019.

The new Loan Notes will bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares from 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10. This initial conversion price equals the nominal value of Esperite’s shares and exceeds the share price at the time the possible issuance of the note was being discussed and negotiated between Esperite and the third party investors, and between the Non-Executive Directors and Mr. Amar. Mr. Amar has not participated in the decision-making of the Board of Directors regarding the extension of the Loan Notes held (in)directly by him. The conversion price may be adjusted in a limited number of customary circumstances. The Loan Notes will mature on 30 June 2021, unless earlier converted or repurchased. The Loan Notes will not be listed.

Frederic Amar, CEO: *“We have previously announced our intentions to reposition our strategy and to structure our company in a more efficient way. The recently announced intentions to sell a historical and major part of our assets is a clear sign for this work in progress. Our company needs time to reach its optimum shape. Esperite is thankful for the support of its external investors. I am personally glad and honoured to contribute financially to this project”.*

About ESPERITE N.V.

ESPERITE Group (Euronext: ESP), listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – ir@esperite.com or visit the website at www.esperite.com.

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).